UnitedHealth Group Inc. — Q2 2012 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2012; filed August 7, 2012. UnitedHealth Group operates UnitedHealthcare, providing health coverage and benefits, and Optum, providing health services, technology and pharmacy benefit management.
Financial performance
| Metric | Q2 2012 | Q2 2011 | Six months 2012 | Six months 2011 |
|---|---|---|---|---|
| Revenue | $27.265B | $25.234B | $54.547B | $50.666B |
| Operating earnings | $2.226B | $2.099B | $4.543B | $4.320B |
| Net earnings | $1.337B | $1.267B | $2.725B | $2.613B |
| Diluted EPS | $1.27 | $1.16 | $2.59 | $2.38 |
| Medical care ratio | 81.3% | 81.4% | 81.1% | 81.4% |
| Operating margin | 8.2% | 8.3% | 8.3% | 8.5% |
| Net margin | 4.9% | 5.0% | 5.0% | 5.2% |
- Q2 revenue rose 8%, net earnings 6% and diluted EPS 9% year over year. For the first half, revenue rose 8%, net earnings 4% and diluted EPS 9%.
- Medical costs increased 8% in Q2, alongside revenue growth; management attributed higher costs to membership growth, unit-cost inflation (especially hospital prices) and moderately higher utilization. The medical care ratio improved slightly, but operating and net margins declined.
- Q2 segment results: UnitedHealthcare revenue was $25.5B and operating earnings $1.906B. Optum revenue was $7.3B and operating earnings $320M, down 6% year over year. OptumHealth revenue grew 21%, but earnings fell 9%; OptumRx earnings fell 14%, while OptumInsight earnings grew 9%.
- Management reported $620M of favorable medical cost development related to prior years in the first half, versus $560M in the prior-year period. Q2 included $90M of prior-year favorable development and $120M related to the current year. Lower-than-expected utilization was a principal factor.
Cash flow, balance sheet and capital
- First-half operating cash flow was $5.771B, versus $2.419B in 2011. The increase was substantially affected by receipt on June 29 of approximately $2.7B for July CMS premiums, recorded as unearned revenue. Management expected lower year-over-year operating cash flow for full-year 2012, including payment of 2011 premium rebates in Q3.
- First-half investing cash outflow was $3.403B, including $2.404B net cash paid for acquisitions. Financing cash outflow was $219M, including $1.809B of share repurchases and $386M of dividends. Cash and cash equivalents ended June at $11.578B, up from $9.429B at year-end.
- At June 30, total assets were $73.465B and shareholders’ equity $29.375B. Long-term debt carrying value was $12.617B, including current maturities; debt-to-debt-plus-equity was 30.0%, up from 29.1% at year-end. The company reported compliance with debt covenants and no borrowings under its $3.0B revolving credit facility or commercial paper outstanding.
- Cash, cash equivalents and available-for-sale investments totaled approximately $30.7B; $1.0B of cash was held by non-regulated entities. Regulated-subsidiary dividends and distributions are subject to restrictions. The investment portfolio had a 1.9-year weighted-average duration and AA weighted-average credit rating.
- In the first half, the company repurchased 33M shares for $1.8B at an average $55.03 per share. The board authorized repurchases of up to 110M shares in June, with 109M remaining authorized at quarter-end. The annual dividend rate was raised from $0.65 to $0.85 per share.
Outlook, risks and notable items
- No specific consolidated earnings or revenue guidance is provided in the supplied filing text. Management expected steadily increasing medical utilization and higher prescription drug costs through the rest of 2012, continued pressure on government reimbursement, and highly competitive commercial pricing into 2013.
- Health reform creates uncertainty around premium rebates, rate review, Medicare Advantage funding, 2014 industry fees and exchange implementation. Management cited risk of margin compression if commercial premiums cannot keep pace with medical costs, and noted Medicare Advantage benchmark reductions and possible sequestration cuts beginning in 2013.
- CMS’s revised risk-adjustment data validation audit methodology could lead to retrospective payment adjustments; the company could not estimate potential losses. State Medicaid rate pressure and commercial competition were also cited.
- A California claims-processing proceeding concerns 908,654 alleged violations; regulators indicated they were seeking approximately $325M in penalties. The company disputes the claims and said it could not reasonably estimate a potential loss. Other litigation and government inquiries also carry uncertain outcomes.
- Membership increased 5% overall in UnitedHealthcare medical plans, including 18% growth in Medicare Advantage and 11% in Medicaid. Commercial risk-based membership declined 2%; stand-alone Medicare Part D membership declined 12%, partly following the loss of approximately 470,000 low-income subsidy beneficiaries.
- The GAO affirmed UnitedHealthcare’s TRICARE West contract award in July. The five-year base administrative services contract is expected to generate $1.4B in revenue; operations were anticipated to begin April 1, 2013.
- After quarter-end, in August 2012, the company exchanged $1.080B of zero-coupon notes for additional notes and $138M cash, a transaction management said was intended to increase financial flexibility and reduce interest expense.
Most important facts for investors to verify
- How much of reported operating cash flow reflects timing of the early CMS premium payment, and the subsequent payment of premium rebates.
- Whether medical utilization, hospital unit costs and prescription drug costs develop as management expected, and whether favorable medical cost development persists.
- Segment profitability trends, particularly OptumHealth and OptumRx margins amid investment spending and lower Part D volumes.
- Potential effects of Medicare and Medicaid reimbursement changes, health reform implementation, premium rate regulation and 2014 industry fees.
- Developments in the California regulatory proceeding and CMS risk-adjustment audits, for which potential losses were not estimable.